Painkiller-blood thinner combo under scrutiny in cancer patients
NCT ID NCT07384013
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how metamizole (Optalgin), a common painkiller, changes the levels of blood thinners (apixaban or rivaroxaban) in cancer patients. Researchers will measure drug concentrations at several time points in 30 adults. The goal is to understand if metamizole interferes with these anticoagulants, which could affect bleeding or clotting risks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
metamizole (Optalgin)
What this could lead to
If successful, this could help doctors safely combine metamizole with blood thinners in cancer patients, reducing bleeding or clotting risks.
What could go wrong
This is a small, early-stage observational study with only 30 participants, so results may not apply broadly. It does not test a new treatment, only measures drug interactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAIN MANAGEMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Rambam Health Care Campus
RECRUITINGHaifa, 31096, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••